Evaluation of safety and efficacy of Dermaveel in treatment of atopic dermatitis

Dermaveel cream, which has been registered for the use in atopic dermatitis (AD), consists of, among others, ectoine and hazel bark extract. To evaluate safety, efficacy and tolerance of the preparation, 242 subjects with AD were included in open-label studies in 64 research sites in Poland. Dermaveel cream was applied to affected skin 2x daily for 4 weeks. Patients came for follow-up visits three times - at the beginning of the study and then once every two weeks. Intensity of skin changes was evaluated with the use of SCORAD index and intensity of pruritus and sleep disorders were assessed with the use of analogue scale of 1-10. Reduction of the mean SCORAD index from 42 at visit I to 25 at visit II and to 15 at visit III was observed. Statistically significant reduction of intensity of pruritus and sleep disorders at follow-up visits has also been shown. During the study, patients also evaluated usable properties of the study cream considering ease of spreading, absorption rate, consistency, and smell. Almost all patients assessed these properties as very good or good. On the basis of the conducted study, it has been concluded that Dermaveel cream is a safe and efficient preparation. It can be recommended for use on all parts of the body both in children and adults. Its regular use may reduce the need for topical glucocorticosteroids but it requires further studies. (C) 2015 Polish Society of Allergology. Published by Elsevier Sp. z o. o. All rights reserved.